Use of Xanthinol Nicotinate as a co-treatment for radio- and chemo-therapy in experimental tumors

International Journal of Cancer

Volumn 126, Issue 2, 2010, Pages 583-588

  Segers, Jérome ^a   Crokart, Nathalie ^a   Danhier, Pierre ^a,b   Grégoire, Vincent ^a   Jordan, Bénédicte F ^a,b   Gallez, Bernard ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b FNRS (Belgian Funds for Scientific Research)   (Belgium)

Author keywords

Chemotherapy; EPR; MRI; Radiotherapy; Tumor; Xanthinol nicotinate

Indexed keywords

CYCLOPHOSPHAMIDE; XANTHINOL NICOTINATE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER TRANSPLANTATION; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG EFFICACY; ELECTRON SPIN RESONANCE; EXPERIMENTAL NEOPLASM; HEMODYNAMICS; HYPOXIA; IN VIVO STUDY; MALE; MICROENVIRONMENT; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION; PERMEABILITY; PRIORITY JOURNAL; RADIATION RESPONSE; RADIOSENSITIZATION; REOXYGENATION; SINGLE DRUG DOSE; TREATMENT RESPONSE; TUMOR RESISTANCE; X RAY;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; HEMODYNAMICS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS, EXPERIMENTAL; RADIATION-SENSITIZING AGENTS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; VASODILATOR AGENTS; X-RAY THERAPY; XANTHINOL NIACINATE;

EID: 73449149271     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24724     Document Type: Article

References (21)

1. Menon C, Fraker DL. Tumor oxygenation status as a prognostic marker. Cancer Lett 2005;221:225-35.
2. Zhou J, Schmid T, Schnitzer S, Brüne B. Tumor hypoxia and cancer progression. Cancer Lett 2006:237;10-21.
3. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8:967-75.
4. Feron O. Targeting the tumor vascular compartment to improve conventional cancer therapy. TRENDS Pharmacol Sci 2004;25:536-542.
5. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
6. Ansiaux R, Baudelet C, Jordan BF, Beghein N, Sonveaux P, De Wever J, Martinive P, Grégoire V, Feron O, Gallez B. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-50.
7. Segers J, Di Fazio V, Reginald A, Martinive P, Feron O, Wallemacq P, Gallez B. Potentiation of cyclophosphamide chemotherapy using the antiangiogenic drug thalidomide: importance of optimal scheduling to exploit the normalization window of the tumor vasculature. Cancer Lett 2006;244:129-35.
8. Jordan BF, Grégoire V, Demeure RJ, Sonveaux P, Feron O, O'Hara JA, Vanhulle VP, Delzenne N, Gallez B. Insulin increases the sensitivity of tumors to irradiation: involvement of an increase in tumor oxygenation mediated by a nitric oxide-dependent decrease of the tumor cells oxygen consumption. Cancer Res 2002;62:3555-61.
9. Jordan BF, Beghein N, Aubry M, Grégoire V, Gallez B. Potentiation of radiation-induced regrowth delay by isosorbide dinitrate in FSaII murine tumors. Int J Cancer 2003;103:138-41.
10. Jordan BF, Sonveaux P, Feron O, Grégoire V, Beghein N, Gallez B. Nitric oxide-mediated increase in tumor blood flow and oxygenation of tumors implanted in muscles stimulated by electric pulses. Int J Radiat Oncol Biol Phys 2003;55:1066-73.
11. Sonveaux P, Jordan BF, Gallez B, Feron O. Nitric oxide delivery to cancer: Why and how? Eur J Cancer 2009;45:1352-69.
12. Jordan BF, Christian N, Crokart N, Grégoire V, Feron O, Gallez B. Thyroid status is a key modulator of tumor oxygenation: implication for radiation therapy. Radiat Res 2007;168:428-32.
13. Gallez B, Jordan BF, Baudelet C, Misson PD. Pharmacological modifications of the partial pressure of oxygen in murine tumors: evaluation using in vivo EPR oximetry. Magn Reson Med 1999;42:627-30.
14. Bieron K, Swies J, Kostka-Trabka E, Gryglewski RJ. Thrombolytic and antiplatelet action of xanthinol nicotinate: possible mecanisms. J Physiol Pharmacol 1998;49:241-9.
15. Lehmanne E, Van Der Crone L, Grobe-Einsler R, Linden M. Drug-monitoring study (phase IV) of xanthinol nicotinate (complamin) in general practice. Pharmacopsychiatry 1993;26:42-8.
16. Taper HS, Woolley GW, Teller MN, Lardis MP. A new transplantable mouse liver tumor of spontaneous origin. Cancer Res 1966;26:143-8.
17. Gallez B, Baudelet C, Jordan BF. Assessment of tumor oxygenation by electron paramagnetic resonance: principles and applications. NMR Biomed 2004;17:240-62.
18. Sersa G, Cemazar M, Miklavcic D, Chaplin DJ. Tumor blood flow modifying effect of electrochemotherapy with bleomycin. Anticancer Res 1999;19:4017-22.
19. Baudelet C, Ansiaux R, Jordan BF, Havaux X, Macq B, Gallez B. Physiological noise in murine solid tumors using T2*-weighted gradient-echo imaging: a marker of tumour acute hypoxia? Phys Med Biol 2004;49:3389-411.
20. Galbraith SM, Maxwell RJ, Lodge MA, Tozer GM, Wilson J, Taylor NJ, Stirling JJ, Sena L, Padhani AR, Rustin GJ. Combretastatin A4 Phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
21. Ansiaux R, Baudelet C, Jordan BF, Crokart N, Martinive P, DeWever J, Grégoire V, Feron O, Gallez B. Mechanism of reoxygenation after antiangiogenic therapy using SU5416 and its importance for guiding combined antitumor therapy. Cancer Res 2006;66:9698-704.